Bengt Westrin

Dr Bengt Westrin joined Ventac Partners in June 2010. He has 23 years industry experience spanning from startups to big pharma, and from product development and regulatory affairs to project management and business development. Prior to joining Ventac Partners he was CEO at the Karolinska Development company Lipopeptide AB in Stockholm and prior to that, VP Business Development at the drug delivery company Camurus AB, Lund. During 2009 to 2014 he was CEO of Idogen AB, Lund, which was co-founded by Ventac Partners in 2008, and was then Chairman of the Idogen Board until March 2015. During 2011-2014 he was part time CEO of AcuCort AB in Helsingborg, Sweden, which develops a reformulated oral glucocorticoid product. Today however he spends the bulk of his time on the position as CEO of CombiGene AB (publ), Lund, which develops a gene therapy method against epilepsy and which is listed on the Swedish stock exchange AktieTorget. Dr. Westrin received his MSc and his PhD at the Faculty of Engineering at Lund University, where he is also Associate Professor since 1999.

Subscribe to our Newsletter

Thank you!